‘Chase’: in dogged pursuit of a therapy for spinal cord injury

12. Liao Y, Deprez L, Maljevic S, Pitsch J, Claes L, Hristova D, et al. Molecular correlates of age-dependent seizures in an inherited neonatal-infantile epilepsy. Brain 2010; 133: 1403–14. Ogiwara I, Miyamoto H, Morita N, Atapour N, Mazaki E, Inoue I, et al. NaV1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation. J Neurosci 2007; 27: 5903–14. Oyrer J, Maljevic S, Scheffer IE, Berkovic SF, Petrou S, Reid CA. Ion channels in genetic epilepsy: from genes and mechanisms to disease-targeted therapies. Pharmacol Rev 2018; 70: 142–73. Schattling B, Fazeli W, Engeland B, Liu Y, Lerche H, Isbrandt D, Friese MA. Activity of NaV1.2 promotes neurodegeneration in an animal model of multiple sclerosis. JCI Insight. 2016; 1: e89810. Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent ion channels in mammalian central neurons. Physiol Rev 2008; 88: 1407–47. Valtorta F, Benfenati F, Zara F, Meldolesi, J. PRRT2: from paroxysmal disorders to regulation of synaptic function. Trends Neurosci 2016; 39: 668–79. Wagnon JL, Meisler MH. Recurrent and non-recurrent mutations of SCN8A in epileptic encephalopathy. Front Neurol 2015; 6: 104. Wolff M, Johannesen KM, Hedrich UBS, Masnada S, Rubboli G, Gardella E et al. Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2Arelated disorders. Brain 2017; 140: 1316–36.